Olr768 inhibitors represent a specific class of chemical compounds designed to target and inhibit the activity of the Olr768 receptor, a protein that belongs to the olfactory receptor family. These receptors are part of the G protein-coupled receptor (GPCR) superfamily, which are characterized by their seven-transmembrane domain structure. The inhibition of Olr768 receptors involves the binding of the inhibitor molecule to the active site of the receptor, effectively blocking its ability to interact with its natural ligands. This blockade can result in the modulation of various biological pathways that are downstream of the receptor activation. The design and synthesis of Olr768 inhibitors require a deep understanding of the receptor's structure, the binding site's topology, and the molecular dynamics involved in receptor-ligand interactions. These inhibitors can vary significantly in their chemical structures, ranging from small organic molecules to larger, more complex entities, all tailored to fit the unique binding pocket of the Olr768 receptor.
The development of Olr768 inhibitors involves extensive research in molecular biology, chemistry, and biophysics. High-throughput screening methods are often employed to identify potential inhibitor candidates from large chemical libraries. Once potential inhibitors are identified, they undergo rigorous structural optimization to enhance their affinity and specificity for the Olr768 receptor. Techniques such as X-ray crystallography, NMR spectroscopy, and computational modeling are commonly used to elucidate the binding interactions at the molecular level. This information is crucial for refining the chemical structure of inhibitors to achieve the desired inhibitory effects. Additionally, the study of the physicochemical properties of these inhibitors, including their solubility, stability, and permeability, is essential for understanding their behavior in biological systems. Overall, Olr768 inhibitors serve as vital tools in the exploration of olfactory receptor functions and the broader GPCR signaling mechanisms, contributing to our knowledge of cellular communication and molecular recognition processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
EGFR inhibitor, potentially affecting proteins in the epidermal growth factor receptor pathway. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially impacting proteins involved in apoptosis regulation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, potentially affecting proteins in cytokine signaling pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL kinase inhibitor, potentially affecting proteins in leukemia-related pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor, potentially disrupting proteins in the MAPK/ERK pathway. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
EGFR inhibitor, potentially targeting proteins in the epidermal growth factor receptor pathway. | ||||||
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
CYP17 inhibitor, potentially affecting androgen synthesis and related protein pathways. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
MET, VEGFR2, and RET inhibitor, potentially impacting proteins in related signaling pathways. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
BRAF inhibitor, potentially affecting proteins in the MAPK/ERK pathway. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Bruton's tyrosine kinase inhibitor, potentially affecting proteins in B-cell receptor signaling pathways. | ||||||